juin 3, 2018 | Posted by admin
Un nouvel article scientifique intitulé «Prevalence of degenerative changes and overlap with spondyloarthritis-associated lesions in the spine of patients from the DESIR cohort» a été publié dans le journal RMD Open.
de Bruin F, Treyvaud MO, Feydy A, de Hooge M, Pialat JB, Dougados M, Gossec L, Bloem JL, van der Heijde D, Reijnierse M.
Objectives:
To describe the prevalence of degenerative changes on MRI and conventional radiographs of the spine in a young population with suspicion of axial spondyloarthritis (axSpA) and assess whether it is possible to discriminate between degenerative changes and lesions associated with axSpA.
Methods:
Whole spine MRI and cervical and lumbar radiographs of patients ≥18 years with chronic back pain (≥3 months, ≤3 years, onset <50 years) were assessed for degeneration by two readers, and for SpA lesions by two other readers, all blinded for clinical information and results of the other readers. Degenerative scores were adjudicated in case of disagreement (by a third reader). Patients fulfilling and not fulfilling the Assessment of SpondyloArthritis international Society axSpA criteria were compared for prevalence of degenerative lesions. Scores for degenerative and SpA lesions were compared, and overlap was defined as the presence of both types of lesions in a single vertebral unit (VU).
Results:
In 456/648 (70.4%) patients (46.8% men, mean age 33.6), degenerative lesions were found with similar percentages in patients with no axSpA and with axSpA (72.4% and 69.2%, p=0.45). Modic changes were found more often in patients with no axSpA (29/239, 12.1%) versus patients with axSpA (19/409, 4.6%, p=0.01). Other lesions were evenly distributed. Overlap was minimal in 19 patients (3.0%) and 32/14 674 (0.2%) VUs for SpA reader 1 and in 23 patients (3.6%) and 34/14 674 VUs (0.2%) for SpA reader 2.
Conclusion:
The prevalence of degeneration is high in an early inflammatory back pain cohort. Discrimination between degeneration and axSpA lesions is very well possible with little overlap between degenerative and axSpA readings.
KEYWORDS:
ankylosing spondylitis; low back pain; magnetic resonance imaging; spondyloarthritis
Categories: Publication de travaux dans des journaux médicaux | 
Tags: | 
No Comments »
mai 27, 2018 | Posted by admin
Un nouvel article scientifique intitulé «Increase In Il-31 Serum Levels Is Associated With Reduced Structural Damage In Early Axial Spondyloarthritis.» a été publié dans le journal Sci Rep.
Rosine N, Etcheto A, Hendel-Chavez H, Seror R, Briot K, Molto A, Chanson P, Taoufik Y, Wendling D, Lories R, Berenbaum F, van den Berg R, Claudepierre P, Feydy A, Dougados M, Roux C, Miceli-Richard C.
ABSTRACT:
In spondyloarthritis, little is known about the relation between circulating cytokines and patient phenotype. We have quantified serum levels of T helper type 1 cell (Th1), Th2 and Th17 cytokines in patients with recent-onset axial spondyloarthritis (AxSpA) from the DESIR cohort, a prospective, multicenter French cohort consisting of 708 patients with recent-onset inflammatory back pain (duration >3 months but <3 years) suggestive of AxSpA. Serum levels of Th1, Th2, and Th17 cytokines were assessed at baseline in patients from the DESIR cohort fulfilling the ASAS criteria (ASAS+) and were compared with age- and sex-matched healthy controls. At baseline, ASAS+ patients (n = 443) and healthy controls (n = 79) did not differ in levels of most of the Th1, Th2 and Th17 cytokines except for IL-31, and sCD40L, which were significantly higher for ASAS+ patients than controls (p < 0.001 and p = 0.012, respectively). On multivariable analysis of ASAS+ patients, IL-31 level was associated with sCD40L level (p < 0.0001), modified Stoke AS Spine Score (mSASSS) < 1 (p = 0.035). The multivariable analyses showed that IL-31 was an independent factor associated with mSASSS < 1 (p = 0.001) and low bone mineral density (p = 0.01). Increased level of IL-31 might protect against structural damage but is also related to low BMD.
Categories: Publication de travaux dans des journaux médicaux | Tags: | No Comments »
mai 12, 2018 | Posted by admin
Un nouvel article scientifique intitulé «Adherence to recommendations for the use of anti-tumour necrosis factor and its impact over 5 years of follow-up in axial spondyloarthritis.» a été publié dans le journal Rheumatology (Oxford).
López-Medina C, Dougados M, Collantes-Estévez, Moltó A.
Abstract
OBJECTIVES:
To describe adherence to recommendations for TNFα blocker (TNFb) initiation and continuation in early axial Spondyloarthropathy (axSpA); and to evaluate the impact of adherence to these recommendations over 5 years of follow-up in the DEvenir des Spondyloarthrites Indifférenciées Récentes (DESIR) cohort.
METHODS:
The first 5 years of follow-up of the DESIR early axSpA cohort were analysed. We evaluated adherence to Assessment of SpondyloArthritis International Society (ASAS) 2003/2006, 2016 and European Medicines Agency recommendations in axSpA patients for: TNFb initiation (patients were adherent if they either commenced TNFb therapy when they met the conditions for initiation or if they did not commence TNFb therapy when conditions were not met) and; TNFb continuation (either when they continued TNFb therapy when conditions to continue were met or when they discontinued when conditions were not met). The impact of adherence to these recommendations on functional disability, quality of life and sick-leave days over 5 years was explored.
RESULTS:
A total of 708 patients were analysed: 440 (62.15%), 389 (54.94%) and 335 (47.32%) were considered adherent to ASAS 2003/2006, 2016 and European Medicines Agency recommendations for TNFb initiation, respectively. Adherence to 2003/2006 and 2016 recommendations for TNFb continuation was observed in 47.37 and 49.39% of patients, respectively. According to over 5 years of follow-up, better outcomes (lower BASFI, higher SF-36 and fewer days of sick leave) were found in patients adhering to recommendations for TNFb commencement and continuation.
CONCLUSION:
Less than 50% of patients were treated in agreement with recommendations for TNFb initiation and continuation. Nevertheless, adherence to such recommendations leads to better functional outcomes and fewer days of sick leave, according to long-term follow-up.
Categories: Publication de travaux dans des journaux médicaux | Tags: | No Comments »
mars 19, 2018 | Posted by admin
Un nouvel article scientifique intitulé » In patients with axial spondyloarthritis, inflammation on MRI of the spine is longitudinally related to disease activity only in men: 2 years of the axial spondyloarthritis DESIR cohort » a été publié dans le journal Ann Rheum Dis.
Navarro-Compán V, Ramiro S, Landewé R3, Dougados M, Miceli-Richard C, Richette P, van der Heijde D.
Ann Rheum Dis. 2017 Mar 3. pii: annrheumdis-2016-210697. doi: 10.1136/annrheumdis-2016-210697. [Epub ahead of print]
KEYWORDS:
Disease Activity; Magnetic Resonance Imaging; Spondyloarthritis
Categories: Publication de travaux dans des journaux médicaux | Tags: | No Comments »
février 21, 2018 | Posted by admin
Bonjour,
Nous mettons en ligne aujourd’hui la nouvelle Newsletter rhumatologues rédigée par le Dr A. Feydy, rhumatologue à Cochin .
Pour y avoir accès, merci de consulter le lien suivant: cliquer ici.
Categories: Newsletter Radiologues | Tags: | No Comments »
février 21, 2018 | Posted by admin
Bonjour,
Nous mettons en ligne aujourd’hui la nouvelle Newsletter rhumatologues rédigée par le Pr F Berenbaum, rhumatologue à Saint Antoine .
Pour y avoir accès, merci de consulter le lien suivant: cliquer ici.
Categories: Newsletter Rhumatologues | Tags: | No Comments »
février 21, 2018 | Posted by admin
Bonjour,
Nous mettons en ligne aujourd’hui la nouvelle Newsletter patients rédigée par le Pr C Miceli, rhumatologue au CHU de Cochin.
Pour y avoir accès, merci de cliquer ici.
Categories: Newsletter Patients | Tags: | No Comments »
février 21, 2018 | Posted by admin
Nous mettons en ligne aujourd’hui la nouvelle Newsletter patients rédigée par le Pr L. Gossec, rhumatologue au CHU La pitié Salpêtrière.
Pour y avoir accès, merci de cliquer ici.
Categories: Newsletter Patients | Tags: | No Comments »
février 20, 2018 | Posted by admin
Bonjour,
Nous mettons en ligne aujourd’hui la nouvelle Newsletter patients rédigée par le Pr P Claudepierre , rhumatologue au CHU Henri Mendor.
Pour y avoir accès, merci de cliquer ici.
Categories: Newsletter Patients | Tags: | No Comments »
février 5, 2018 | Posted by admin
Un nouvel article scientifique intitulé «Evaluation of the change in structural radiographic sacroiliac joint damage after 2 years of etanercept therapy (EMBARK trial) in comparison to a contemporary control cohort (DESIR cohort) in recent onset axial spondyloarthritis.» a été publié dans le journal Ann Rheum Dis .
Dougados M, Maksymowych W, Landewé RB, Moltó A, Claudepierre P, de Hooge M, Lambert RG, Bonin R, Bukowski JF, Jones HE, Logeart I, Pedersen R, Szumski A, Vlahos B, van der Heijde D.
Abstract
OBJECTIVE:
To compare 2 years of radiographic sacroiliac joint (SIJ) changes in patients with recent onset axial spondyloarthritis (axSpA) receiving etanercept in a clinical trial (EMBARK) to similar patients not receiving biologics in a cohort study (DESIR).
METHODS:
Endpoints were changes at week 104 per the modified New York (mNY) grading system in total SIJ score (primary endpoint) and net percentage of patients with progression defined three ways. Treatment effect was analysed with and without adjustment for baseline covariates.
RESULTS:
At 104 weeks, total SIJ score improved in the etanercept group (n=154, adjusted least-squares mean change: -0.14) and worsened in the control group (n=182, change: 0.08). The adjusted difference between groups (etanercept minus control) was -0.22 (95% CI -0.38 to -0.06), p=0.008. The net percentage of patients with progression was significantly lower in the etanercept versus the control group for two of three binary endpoints: -1.9% versus 1.6% (adjusted difference for etanercept minus control: -4.7%,95% CI -9.9 to 0.5, p=0.07) for change in mNY criteria; -1.9% versus 7.8% (adjusted difference: -18.2%,95% CI -30.9 to -5.6, p=0.005) for change ≥1 grade in ≥1 SIJ; and -0.6% versus 6.7% (adjusted difference: -16.4%,95% CI -27.9 to -5.0, p=0.005) for change ≥1 grade in ≥1 SIJ, with shift from 0 to 1 or 1 to 0 considered no change.
CONCLUSION:
Despite the slow radiographic SIJ progression rate over 2 years in axSpA, this study suggests a lower rate of progression in the SIJ with etanercept than without anti-tumour necrosis factor therapy.
TRIAL REGISTRATION NUMBERS:
NCT01258738,NCT01648907; Post-results.
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
KEYWORDS:
anti-tnf; spondyloarthritis; treatment
Categories: Publication de travaux dans des journaux médicaux | Tags: | No Comments »
